Junhui Sun*1, Guanhui Zhou*1, Xiaoxi Xie†, Wenjiang Gu‡, Jing Huang§, Dedong Zhu¶, Wenhao Hu#, Qinming Hou**, Changsheng Shi††, Tiefeng Li‡‡ , Xin Zhang§§, Wenbin Ji¶¶, Shihong Ying§§,
Zhiyi Peng§§, Jian Zhou##, Zhihai Yu***, Jiansong Ji†††, Haijun Du‡‡‡, Xiaohua Guo§§§,
Jian Fang¶¶¶, Jun Han###, Huanhai Xu****, Zhichao Sun††††, Wenqiang Yu‡‡‡‡, Guoliang Shao§§§§,
Xia Wu¶¶¶¶ ,Hongjie Hu¶¶¶¶ , Ling Li#, Jiaping Zheng§§§§, Jun Luo§§§§, Yutang Chen§§§§,
Guohong Cao####, Tingyang Hu‡‡‡‡
Oncology Research, Vol.28, No.1, pp. 75-94, 2020, DOI:10.3727/096504019X15662966719585
Abstract The purpose of this study was to investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) treatment in Chinese hepatocellular carcinoma (HCC) patients and the prognostic
factors for treatment response as well as survival. A total of 275 HCC patients were included in this prospective study. Treatment response was assessed by modified Response Evaluation Criteria in Solid Tumors
(mRECIST), and progression-free survival (PFS) as well as overall survival (OS) were determined. Liver function and adverse events (AEs) were assessed before and after DEB-TACE operation. Complete response
(CR), partial response (PR), and objective response… More >
Login
Register
